CTLA4 and neoplasm: These agents target key regulatory pathways, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand PD-L1, to overcome tumor-induced immune suppression.